Accedi
Accedi
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrazione
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Home
  2. Azioni
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Abbisko Cayman Limited
  6. Notizie
  7. Altre lingue
    2256   KYG0028A1085

ABBISKO CAYMAN LIMITED

(2256)
  Rapporto
Tempo differito Hong Kong Stock Exchange  -  10:08 27/09/2022
3.290 HKD   -0.30%
17/05Abbisko Cayman nomina un nuovo CFO; le azioni saltano del 3%.
MT
27/04Abbisko Cayman Limited annuncia cambiamenti nell'Esecutivo, nel Consiglio di Amministrazione e nei Comitati
CI
18/03Abbisko Cayman allarga la perdita su spese più alte nel 2021
MT
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietąFinanzaConsensusRevisioniDerivatiFondi 
RiassuntoTutte le notizieAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su ABBISKO CAYMAN LIMITED
08:41Abbisko Doses First Patient in China Clinical Trial of Cancer Drug
19/09Abbisko Cayman Limited(SEHK:2256) dropped from S&P Global BM..
20/07Chinese Regulator Grants Therapy Designation to Abbisko Cayman's Inhibitor
04/07Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Se..
04/07Abbisko Cayman Unit Completes Dosing of 1st Patient in Advanced Solid Tumor Treatment T..
17/05Abbisko Cayman Appoints New CFO; Shares Jump 3%
17/05Abbisko Cayman Limited Appoints Zhang Zidong as Chief Financial Officer
27/04Abbisko Cayman Limited Announces Resignation of Yeh Richard as Chief Financial Officer,..
27/04Abbisko Cayman Limited Announces Executive, Board and Committee Changes
12/04641,428,350 Ordinary Shares of Abbisko Cayman Limited are subject to a Lock-Up Agreemen..
01/04Abbisko Unit Gets Nod to Start Clinical Trial in China of Immunotherapy
21/03Abbisko Cayman Limited(SEHK:2256) added to S&P Global BMI In..
18/03Abbisko Cayman Widens Loss on Higher Expenses in 2021
18/03Abbisko Cayman Limited Reports Earnings Results for the Full Year Ended December 31, 20..
07/03US FDA Grants Orphan Drug Status to Gastric Cancer Treatment of Abbisko Arm
03/03Chinese Regulators OK Abbisko Arm's Investigational New Drug Application for Solid Tumo..
15/02Abbisko Arm to Hold Clinical Study of Combination Urothelial Cancer Treatment
11/02Abbisko Cayman Limited commences an Equity Buyback Plan for 10% of its issued share cap..
08/02Abbisko Doses First Patient in China Phase II Trial of Hepatocellular Carcinoma Therapy..
03/02Shenzhen-based Cali Biosciences Files for Hong Kong IPO
18/01Abbisko Therapeutics Announces Worldwide Collaboration with Lilly to Discover and Devel..
2021Abbisko Unit Doses First Patient in China Clinical Study of Rare Tumor Disease Therapy
2021US Biotech Firm Sirnaomics Passes Hong Kong Listing Hearing
2021Abbisko Unit Doses First Patient in China Phase II Trial of Urothelial Cancer Therapy
2021Abbisko Therapeutics Doses First Patient in Giant Tumor Drug Trial in China; Shares Ral..
2021Abbisko Therapeutics Co., Ltd. Announces Dosing of First Patient in the Phase I Clinica..
2021Abbisko's Underwriters Partially Exercise Over-Allotment Option; Shares Slump 4%
2021Abbisko Partner Completes Patient Enrollment for Phase 3 Study of Immunodeficiency Diso..
2021Abbisko Cayman : Therapeutics Gets FDA Nod to Start US Clinical Trial of ..
2021Abbisko Cayman : Wins Approval for Phase II Clinical Trial in China of Ca..
2021Abbisko Therapeutics Co., Ltd. Obtains IND Approval from China National Medical Product..
2021Hong Kong Stocks Finish Week Higher; Abbisko Underwhelms in Debut
2021Abbisko Cayman: Qiming's Portfolio Company Abbisko Lists on Main Board of HKEx
2021Abbisko Cayman : Shares Slide 9% in Hong Kong Debut as Investors Continue..
2021Hong Kong Suspends Full-Day Stock Market `Trading Due to Typhoon; Abbisko's Market Debu..
2021Abbisko Cayman Limited has completed an IPO in the amount of HKD 1.753571 billion.
2021Abbisko Cayman : Raises $207 Million in Hong Kong IPO Ahead of Wednesday ..
2021Abbisko Cayman Limited has filed an IPO in the amount of HKD 1.753571 billion.